Form 4: Corcept CDO Exercises Options, Sells Shares

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a significant portion of the acquired shares under a pre-arranged 10b5-1 plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), engaged in several transactions involving the company's common stock and derivative securities.
• On December 1, 2025, Guyer purchased 224 shares of common stock at $79.78 per share under a purchase plan.
• Also on December 1, 2025, Guyer received 224 shares of unvested restricted stock awards at $0.00, which will vest on the one-year anniversary of the grant date, provided the Purchase Plan Shares are retained.
• On December 2, 2025, Guyer disposed of 787 shares from indirect holdings (The Lake Bainwood Living Trust) via a gift.
• On December 2, 2025, Guyer acquired 787 shares directly without consideration through a transfer.
• On December 2, 2025, Guyer exercised stock options to acquire 20,000 shares of common stock at an exercise price of $21.65 per share.
• Immediately following the option exercise on December 2, 2025, Guyer sold 19,360 shares of common stock at a weighted average price of $80.0499 per share (with actual sale prices ranging from $79.78 to $80.68).
• Additionally, on December 2, 2025, Guyer sold 640 shares of common stock at $80.875 per share.
• Both sales transactions on December 2, 2025, were executed pursuant to a Rule 10b5-1 plan adopted by Guyer on November 27, 2024.
• Following these transactions, Guyer directly beneficially owns 1,235 shares of common stock and 270,000 stock options.

Sentiment

Score: 5

Explanation: The filing details routine insider transactions, including the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. While the officer realized significant gains from the option exercise, the immediate sale of an equivalent number of shares suggests a planned liquidity event rather than a strong bullish or bearish signal. The acquisition of restricted stock is a positive, but the overall net effect on direct ownership is small after the sales. This activity is generally neutral in terms of market sentiment.

Positives

• The Chief Development Officer acquired 224 shares of common stock under a purchase plan, indicating ongoing investment in the company.
• The officer received 224 shares of unvested restricted stock awards, aligning his interests with long-term company performance.
• The exercise of stock options allowed the officer to realize value from previously granted equity compensation.

Negatives

• The immediate sale of 20,000 shares (equivalent to the number of shares acquired through option exercise) could be interpreted as a move to monetize compensation rather than increase direct equity exposure, although it was pre-planned under a 10b5-1 plan.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details routine insider transactions, which are common for executives managing their equity compensation and personal portfolios. The use of a Rule 10b5-1 plan for the sales indicates a pre-scheduled transaction designed to avoid accusations of trading on material non-public information, a standard practice in the industry for corporate insiders.

Related Party Transactions

• A gift of 787 shares was made from indirect holdings (The Lake Bainwood Living Trust), where the Reporting Person is a co-trustee.

Stakeholder Impact

• Shareholders: The transactions represent routine compensation and portfolio management by a key executive and are unlikely to have a significant direct impact on the company's operational or financial performance. The pre-planned nature of the sales mitigates concerns about insider sentiment.
• Employees: No direct impact mentioned.

Next Steps

• The 224 shares of restricted stock awards will vest on the one-year anniversary of the grant date (December 1, 2026), contingent on the Reporting Person remaining the beneficial owner of the Purchase Plan Shares through that date.

Key Dates

Recommendation

The filing details routine insider transactions, including the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. While the officer realized significant gains from the option exercise, the immediate sale of an equivalent number of shares suggests a planned liquidity event rather than a strong bullish or bearish signal. The acquisition of restricted stock is a positive, but the overall activity does not provide new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell based solely on these transactions.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, Share Sale, William Guyer, 10b5-1 Plan, Chief Development Officer, Restricted Stock Awards